Effect on routine and special coagulation testing values of citrate anticoagulant adjustment in patients with high hematocrit values

被引:54
作者
Marlar, Richard A.
Potts, Robyn M.
Marlar, Audrey A.
机构
[1] Univ Oklahoma, Hlth Sci Ctr, Oklahoma City VA Med Ctr, Pathol & Lab Med Serv, Oklahoma City, OK 73104 USA
[2] Univ Oklahoma, Hlth Sci Ctr, Dept Pathol, Oklahoma City, OK 73104 USA
关键词
preanalytic variables; hematocrit; prothrombin time; activated partial thromboplastin time; fibrinogen; protein C;
D O I
10.1309/RRQKT2JEYV33D19D
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Recommendations to adjust citrate concentration for blood coagulation specimens with high hematocrit values are based on indirect experimental studies and not direct studies of patient samples with high hematocrit values. We compared the effect of adjusted and non-adjusted citrate concentrations on coagulation test results in samples from 28 patients with high hematocrit values (55%-72% [0.55-0.72]). Prothrombin time (PT) and activated partial thromboplastin time (aPTT) results from nonadjusted and adjusted samples were statistically different and exponentially increased with increasing hematocrit values. Results for,fibrinogen, factor VIII, and protein C activity were statistically different and increased linearly with increasing hematocrit values; however, the difference was not as clinically significant. The protein C antigen value increased with increasing hematocrit values but was not significant. The effects on PT and of plasma and an aPTT are due to a dilutional effect interference effect of the higherfinal citrate concentration on the clotting test result. For patients with high hematocrit values, citrate concentrations must be adjustedfor accurate results.
引用
收藏
页码:400 / 405
页数:6
相关论文
共 17 条
  • [1] Minimum specimen volume requirements for routine coagulation testing - Dependence on citrate concentration
    Adcock, DM
    Kressin, DC
    Marlar, RA
    [J]. AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 1998, 109 (05) : 595 - 599
  • [2] Adcock DM, 1997, AM J CLIN PATHOL, V107, P105
  • [3] CASTELLONE D, 1999, ADV ADM LAB, P53
  • [4] *CLIN LAB STAND I, 2003, H21A4 CLIN LAB STAND
  • [5] *CLIN LAB STAND I, 2001, H30A2 CLIN LAB STAND
  • [6] *CLIN LAB STAND I, 2001, H47A2 CLIN LAB STAND
  • [7] Activated protein C resistance assay detects thrombotic risk factors other than factor V Leiden
    Graf, LL
    Welsh, CH
    Qamar, Z
    Marlar, RA
    [J]. AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2003, 119 (01) : 52 - 60
  • [8] *INSTR LAB, 1997, INSTR LAB CLAUSS CLO
  • [9] Jensen R., 2000, ADV MED LAB PROFESSI, P90
  • [10] KOEPKE JA, 1975, AM J CLIN PATHOL, V64, P591